Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Osimertinib +/- Bevacizumab in EGFR-mutant NSCLC with LM
NCT04148898Phase 2Unknown
- Sponsor
- The Second Affiliated Hospital of Nanchang University
- Start
- Nov 2019
- Primary completion
- Mar 2021
- Modality
- Monoclonal Antibodies
01
Overview
Phase 2, randomised, open-label trial of bevacizumab in leptomeningeal metastasis (LM) and non-small cell lung cancer (NSCLC) (2 arms), sponsored by The Second Affiliated Hospital of Nanchang University. Primary endpoints: Intracranial Progression-Free Survival and Objective Response Rate. Status: unknown.
02
Drugs
bevacizumab
03
Conditions
leptomeningeal metastasis (LM)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04148898.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04148898.